SEARCH

SEARCH BY CITATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

FilenameFormatSizeDescription
jcph194-sm-0002-SupData-S1.pdf342K

Figure S1. Spiking recovery of apoA-I and phospholipids. Plasma samples of five donors were spiked with control, 0.1, 0.8, and 2.8 mg/mL. (A) Recovery of apoA-I in samples from individual donors. (B) Means ± SD of baseline-adjusted recovery of apoA-I. (C) Recovery of phospholipids in samples from individual donors. Note that there was very little baseline variability between individual samples. (D) Means ± SD of baseline-adjusted recovery of phospholipids.

Figure S2. Pharmacokinetics (24 hours) of PC following the first (left panel) and last (right panel) CSL112 infusion. PC pharmacokinetic profile (baseline-adjusted means ± SD, n = 9) following single and multiple infusions of CSL112. Twenty-four hours-profile following the first (left panel) and last (right panel) infusion of CSL112.

Figure S3. Pharmacokinetics (Full Profile) of PC following the first (left panel) and last (right panel) CSL112 infusion. PC pharmacokinetic profile (baseline-adjusted means ± SD, n = 9) following single and multiple infusions of CSL112. Comparison of Week 1 and Week 4. Note: that dense sampling was conducted for the first and last dose only. Therefore the 2W treatment group shows no dense sampling for the second and the second-to-last infusion in this figure. 1W, once-weekly; 2W, twice-weekly.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.